

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

July 08, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/485,301

FILING DATE: July 05, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/15587

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



A handwritten signature in cursive script, appearing to read "M. Sias".

M. SIAS  
Certifying Officer

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. **82 372374527 US**

INVENTOR(S)					
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)			
Devlin Hai	Dressman Yan	Baltimore, MD Baltimore, MD			
<input checked="" type="checkbox"/> Additional inventors are being named on the 1 separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHOD AND COMPOSITIONS FOR DETECTION AND ENUMERATION OF GENETIC VARIATIONS					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input checked="" type="checkbox"/> Customer Number		22907		Place Customer Number Bar Code Label here	
OR					
<input type="checkbox"/> Firm or Individual Name		Type Customer Number here			
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		31		<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		6		<input checked="" type="checkbox"/> Other (specify) 1 page Supplementary Table	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
FILING FEE AMOUNT (\$)					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		19-0733		80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No.					
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: National Institutes of Health CA 43460, CA 57345, and CA62924.					

Respectfully submitted

SIGNATURE

TYPED or PRINTED NAME

TELEPHONE

Sarah A. Kagan

202 508 9100

Date

07/05/03

REGISTRATION NO.  
(if appropriate)

32,141

Docket Number:

001107.00356

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

17613 U.S. PTO  
60/485301

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number		001107.00356
<b>INVENTOR(S)/APPLICANT(S)</b>		
<b>Given Name (first and middle [if any])</b>	<b>Family or Surname</b>	<b>Residence (City and either State or Foreign Country)</b>
Kenneth W. Bert	Kinzler Vogelstein	Bel Air, MD Baltimore, MD

Number 2 of 2

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**METHOD AND COMPOSITIONS FOR DETECTION AND ENUMERATION OF  
GENETIC VARIATIONS**

- [01] The invention disclosed herein was made using funds from the National Institutes of Health grants CA 43460, CA 57345, and CA62924. The United States government therefore retains certain rights in the invention.
- [02] A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

**FIELD OF THE INVENTION**

- [03] The invention relates to the field of genetic analysis. In particular, it relates to methods and compositions for analyzing variations in individual genes or transcripts and separating variants.

**BACKGROUND OF THE INVENTION**

- [04] The study of DNA sequence variation is essential for many areas of research. The study of germ-line variations is essential for assessing the role of inheritance in normal and abnormal physiologic states (1). Other variations, developed somatically, are responsible for neoplasia (2). The identification of such mutations in urine, sputum, and stool can therefore be used for the detection of presymptomatic cancers (3-5). Similarly, the detection of somatic mutations in lymph nodes, blood, or bone marrow can provide data about the stage of disease, prognosis, and appropriateness of various therapies (5). Somatic mutations in non-neoplastic cells also occur and appear to accumulate as humans age or are exposed to environmental hazards (6). Such mutations occur in only a small fraction of the cells in a tissue, thereby complicating their analysis.

- [05] Central to the investigation of many of these issues is the detection and quantification of sequence variants within a population of DNA molecules. The number of molecules in each such collection is finite and therefore countable. Consider, for example, a collection of red and green balls. Counting these balls is simple in principle but subject to basic probability theory. If there is only one red ball for every 500 green balls, then it is necessary to count several thousand balls to get an accurate estimate of the proportion of red balls. If it is difficult to count enough balls to make a reliable estimate, one can elute the paint off all the balls and measure the color of the resultant paint mix.
- [06] In analogous fashion, small numbers of DNA molecules that vary by subtle changes (single base pair substitutions or small deletions or insertions) can be directly counted by amplifying individual DNA molecules (single molecule PCR) (7-12). Such digital techniques have been shown to be extremely useful for measuring variation in genes or their transcripts. But digital technologies have so far been limited to counting tens to thousands of molecules, either in the wells of microtiter plates, on microscope slides, or after electrophoresis of individual PCR products. Analog techniques, analogous to the elution of paint from the balls described above, are generally easier to implement and can assess millions of molecules simultaneously (13). However, their accuracy and sensitivity is limited by instrumental and experimental noise. There is a continuing need in the art for methods which are accurate and sensitive for measuring variation in genes or their transcripts.

#### BRIEF SUMMARY OF THE INVENTION

- [07] In a first embodiment of the invention a composition is provided. The composition comprises a plurality of beads. Each of the plurality of beads comprises a plurality of bound polynucleotides. The polynucleotides in the composition are heterogeneous; however, on at least 1 % of said beads the plurality of bound polynucleotides is homogeneous.

- [08] In a second embodiment of the invention a liquid composition is provided. The liquid composition comprises a plurality of microemulsions forming aqueous compartments. At least a portion of said aqueous compartments comprise a bead, a polynucleotide template, and oligonucleotide primers for amplifying the template. At least a portion of the oligonucleotide primers is bound to the bead.
- [09] A third embodiment of the invention provides a method for analyzing nucleotide sequence variations. Microemulsions comprising one or more species of analyte DNA molecules are formed. The analyte DNA molecules in the microemulsions are amplified in the presence of reagent beads which are bound to a plurality of molecules of a primer for amplifying the analyte DNA molecules. Product beads are formed that are bound to a plurality of copies of a single species of analyte DNA molecule. The product beads are separated from analyte DNA molecules which are not bound to product beads. A sequence feature of the single species of analyte DNA molecule that is bound to the product beads is determined.
- [10] A fourth embodiment of the invention is a probe for use in hybridization to a polynucleotide that is bound to a solid support. The probe comprises an oligonucleotide with a stem-loop structure. At one of the 5' or 3' ends there is a photoluminescent dye. The oligonucleotide does not comprise a quenching agent at the opposite 5' or 3' end.
- [11] A fifth embodiment of the invention is a pair of molecular probes. The first and second probes each comprise an oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends, and not comprising a quenching agent at the opposite 5' or 3' end. The first oligonucleotide hybridizes to a wild-type selected genetic sequence better than to a mutant selected genetic sequence and the second oligonucleotide hybridizes to the mutant selected genetic sequence better than to the wild-type selected genetic sequence. The first and the second photoluminescent dyes are distinct.

- [12] In a sixth embodiment of the invention a method is provided for isolating nucleotide sequence variants. Microemulsions comprising one or more species of analyte DNA molecules are formed. Analyte DNA molecules in the microemulsions are amplified in the presence of reagent beads. The reagent beads are bound to a plurality of molecules of a primer for amplifying the analyte DNA molecules. Product beads are formed which are bound to a plurality of copies of one species of analyte DNA molecule. The product beads are separated from analyte DNA molecules which are not bound to product beads. The product beads which are bound to a plurality of copies of a first species of analyte DNA molecule are isolated from product beads which are bound to a plurality of copies of a second species of analyte DNA molecule.
- [13] These and other embodiments of the invention, which will be apparent from the entire description of the invention, provide the art with the ability to quantify genetic variations at a scale and ease heretofore unattainable.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- [14] Fig. 1 is a schematic drawing of the BEAMing method. Step 1- Magnetic beads covalently coated with streptavidin are bound to biotinylated oligonucleotides ("oligos"). Step 2 - An aqueous mix containing all the necessary components for PCR plus primer-bound beads and template DNA are stirred together with an oil/detergent mix to create microemulsions. The aqueous compartments (white circles in the gray oil layer) contain an average of <1 template molecule and <1 bead. Red and green templates represent two template molecules whose sequences differ by one or many nucleotides. Step 3 - The microemulsions are temperature cycled as in a conventional PCR. If a DNA template and a bead are present together in a single aqueous compartment, the bead bound oligonucleotides act as primers for amplification. The straight red and green lines connected to the beads represent extension products from the two different kinds of templates. Step 4 - The emulsions are broken and the beads are purified with a magnet. Step 5 - After denaturation, the

beads are incubated with oligonucleotides that can distinguish between the sequences of the different kinds of templates. Fluorescently-labeled antibodies are then used to label the bound hybridization probes. This renders the beads containing PCR product as red or green upon appropriate laser excitation. Step 6 - Flow cytometry is used to count the red and green beads.

- [15] Fig. 2 is a photograph of a typical microemulsion. Microemulsions were made as described infra with the exception that the aqueous compartments contained cascade blue-labeled dCTP and the beads were pre-labeled with phycoerythrin (red) or Alexa 488 (green). One  $\mu$ l of microemulsion was deposited in 1  $\mu$ l of oil on a microscope slide prior to photography. Of the seven aqueous compartments visible in this picture, two contain beads. Note the heterogeneous size of the aqueous compartments (beads are 1.05 microns in diameter).
- [16] Fig. 3A to Fig. 3D show density plots of flow cytometric data obtained from BEAMing. The locus queried in this experiment was MID42 and PCR products generated from genomic DNA were used as templates in the microemulsions. (Fig. 3A) Forward scatter (FSC) and side scatter (SSC) of all beads show that ~80% of the total beads are singlets, with most of the remaining beads aggregated as doublets. The "noise" is instrumental and is observed with blank samples containing no beads. The instrument output was gated so that only singlets were analyzed for fluorescence analysis. The patterns observed from an individual homozygous for the L allele (Fig. 3C), homozygous for the S allele (Fig. 3B), and heterozygous for L and S (Fig. 3D) are shown. The regions containing beads hybridizing to the L and S allele probes are labeled green and red, respectively. The region containing beads that did not hybridize to any probe is black and the region containing beads that hybridized to both probes is blue. The blue beads arose from aqueous compartments in which both types of template molecules were present. The proportion of singlet beads that hybridized to at least one of the probes was 2.9%, 4.3%, and 20.3% in (Fig. 3B) to (Fig. 3D), respectively. The FSC and SSC plots in (Fig. 3A) represent the same beads analyzed in (Fig. 3D).



- [17] Fig. 4A to Fig. 4D show density plots of BEAMing using genomic DNA or RT-PCR products as templates. The data in (Fig. 4A) and (Fig. 4B) were generated by including 10 and 1 ug of human genomic DNA, respectively, in the microemulsions, querying the MID42 locus. The data in (Fig. 4C) and (Fig. 4D) were generated using emulsions that contained ~ 50 pg of PCR products synthesized from cDNA of lymphoblastoid cells, querying the calpain-10 locus. The green and red regions correspond to the L and S alleles for MID42 and to the A and G alleles for calpain-10. The number of beads in the outlined regions containing red or green beads is shown in each case. The proportion of singlet beads that hybridized to at least one of the probes was 1.2%, 0.6%, 6.8% and 4.2% in (Fig. 4A) to (Fig. 4D), respectively. The outlined regions used for counting in (Fig. 4A) and (Fig. 4B) were identical, as were those used for (Fig. 4C) and (Fig. 4D). Beads that did not hybridize to any probe were gated out and therefore not evident in the graphs, while the region containing beads that hybridized to both probes is labeled blue.
- [18] Fig. 5A to Fig. 5C show detection and validation of variants present in a minor fraction of the DNA population. (Fig. 5A) Mixtures of PCR products containing 0% to 4% L alleles of MID42 were used for BEAMing. Flow cytometry such as that shown in Fig. 3 was used to determine the fraction of singlet beads that were red (y-axis). The proportion of singlet beads that hybridized to at least one of the probes varied from 3.2% to 4.3%. (Fig. 5B and Fig. 5C) Beads were sorted with the FACS Vantage SE instrument and individual red or green beads were used as templates for conventional PCR employing the forward and reverse primers listed in Supplementary Table I. Red beads generated only the S allele sequence (Fig. 5B) while green beads generated only the L allele sequence (Fig. 5C).
- [19] Fig. 6A to 6B demonstrate the use of agar in the aqueous phase of the microemulsions. Emulsion bubbles that were formed by including 1.5% agarose in the aqueous compartment are shown. Fig. 6A shows the bubbles that have fluorescents in them. Fig. 6B shows a darkfield image of the bubbles with one of the bubbles containing a bead in it. After breaking the emulsions, the droplets containing

magnetic beads can be recovered by centrifugation and size fractionated through filtration or flow sorting.

#### DETAILED DESCRIPTION OF THE INVENTION

- [20] The inventors describe herein a digital technology, called BEAMing, that has the power to assess millions of molecules and can be generally applied to the study of genetic variation. The technology involves conversion of single DNA molecules to single beads each containing thousands of copies of the sequence of the original DNA molecule. The number of variant DNA molecules in the population can then be assessed, for example, by staining the beads with fluorescent probes and counting them using flow cytometry. Beads representing specific variants can be optionally recovered through flow sorting and used for subsequent confirmation and experimentation.
  
- [21] Beads according to the present invention are also known as microspheres or microparticles. Particle sizes can vary between about 0.1 and 10 microns in diameter. Typically beads are made of a polymeric material, such as polystyrene, although nonpolymeric materials such as silica can also be used. Other materials which can be used include styrene copolymers, methyl methacrylate, functionalized polystyrene, glass, silicon, and carboxylate. Optionally the particles are superparamagnetic, which facilitates their purification after being used in reactions.
  
- [22] Beads can be modified by covalent or non-covalent interactions with other materials, either to alter gross surface properties, such as hydrophobicity or hydrophilicity, or to attach molecules that impart binding specificity. Such molecules include without limitation, antibodies, ligands, members of a specific-binding protein pair, receptors, nucleic acids. Specific-binding protein pairs include avidin-biotin, streptavidin-biotin, and Factor VII-Tissue Factor.

- [23] Beads, after being prepared according to the present invention as product beads, have more than one copy of the same nucleic acid molecule bound to them. Preferably each bead is bound to at least 10, 50, 100, 500, or 1000 molecules of the same nucleic acid sequence. In some circumstances some of the product beads are bound to more than one type of nucleic acid molecule. These product beads are generally less useful in the analysis of ratios of genetic sequences in a population of genetic sequences. Such product beads can be readily discriminated and so will not distort the analysis.
- [24] A population of product beads will often comprise two or more types of nucleic acids. Such a population is heterogeneous with respect to the nucleic acids. Desirably, a substantial proportion of the product beads comprise only one type of nucleic acid per bead. A substantial proportion can be for example, at least 1 %, at least 5 %, at least 10 %, or at least 50 %. A product bead with only one type of nucleic acid per bead is termed homogeneous. Homogeneous beads with only one type of nucleic acid per bead include those with nucleic acids containing errors due to errors in polymerase chain reaction. A product bead with two types of nucleic acid per bead is termed heterogeneous. Although not wishing to be bound by any particular theory, heterogeneous product beads are thought to result from aqueous compartments which have more than two molecules of template of non-identical sequence. A population of product beads can be heterogeneous as a population but contain individual product beads that are homogeneous
- [25] Individual product beads preferably comprise more than one copy of template analyte molecule. Each bead may comprise at least 10, at least 50, at least 100, at least 500, or at least 1000 copies of template analyte. If the bead is homogeneous, each of those copies will be identical.
- [26] Populations of product beads can be maintained in a liquid suspension. Alternatively they can be sedimented and dried or frozen. The latter alternatives may be beneficial for storage stability.

- [27] Analysis of populations of product beads can be useful for distinguishing between many kinds of genetic variants. Polynucleotides can be distinguished which differ by as little as a single nucleotide polymorphism (SNP), by the presence or absence of a mutation, by the presence or absence of an insertion, by the presence or absence of a non-single nucleotide polymorphism. Thus populations of product beads may be heterogeneous with regard to these genetic variations.
- [28] One very convenient way for distinguishing genetic variants, *i.e.*, determining a sequence feature of the analyte, is by differentially labeling the variants with fluorescent dyes. Such labeling can be accomplished by hybridization of a fluorescently labeled oligonucleotide probe to one species of polynucleotide. Alternatively, a fluorescently labeled antibody can be used to specifically attach to one oligonucleotide probe that hybridizes to a particular genetic variant. Such antibody binding can be, for example, mediated by a protein or polypeptide which is attached to an oligonucleotide hybridization probe. Of course, other means of labeling polynucleotides as are known in the art can be used without limitation. Another means of labeling different polynucleotide species is by primer extension. Primers can be extended using labeled deoxyribonucleotides, such as fluorescently labeled deoxyribonucleotides.
- [29] Oligonucleotide primers can be bound to beads by any means known in the art. They can be bound covalently or non-covalently. They can be bound via an intermediary, such as via a protein-protein interaction, such as an antibody-antigen interaction or a biotin-avidin interaction. Other specific binding pairs as are known in the art can be used as well. To achieve optimum amplification, primers bound to the bead may be longer than necessary in a homogeneous, liquid phase reaction. Oligonucleotide primers may be at least 12, at least 15, at least 18, at least 25, at least 35, or at least 45 nucleotides in length. The length of the oligonucleotide primers which are bound to the beads need not be identical to that of the primers that are in the liquid phase. Primers can be used in any type of amplification reaction known in the art, including without limitation, polymerase chain reaction, isothermal amplification, rolling circle

amplification, self-sustaining sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), transcription-mediated amplification (TMA), strand-displacement amplification (SDA), and ligase chain reaction (LCR).

- [30] Microemulsions are made by stirring or agitation of oil, aqueous phase, and detergent. The microemulsions form small aqueous compartments which have an average diameter of 0.5 to 50 microns. The compartments may be from 1 to 10 microns, inclusive, from 11 to 100 microns, inclusive, or about 5 microns, on average. All such compartments need not comprise a bead. Desirably, at least one in 10,000 of said aqueous compartments comprise a bead. Typically from 1/100 to 1/1 or from 1/50 to 1/1 of said aqueous compartments comprise a bead. In order to maximize the proportion of beads which are homogeneous with respect to oligonucleotide, it is desirable that on average, each aqueous compartment contains less than 1 template molecule. Aqueous compartments will also desirably contain whatever reagents and enzymes are necessary to carry out amplification. For example, for polymerase chain reaction (PCR) the compartments will desirably contain a DNA polymerase and deoxyribonucleotides. For rolling circle amplification a DNA polymerase and a generic DNA circle may be present.
  
- [31] Emulsions can be "broken" or disrupted by any means known in the art. One particularly simple way to break the emulsions is to add more detergent. Detergents which can be used include, but are not limited to Triton X100, Laureth 4, Nonidet.
  
- [32] Sample DNA for amplification and analysis according to the present invention can be genomic DNA, cDNA, PCR products of genomic DNA, or PCR products of cDNA, for example. Samples can be derived from a single individual, for example, from a body sample such as urine, blood, sputum, stool, tissue or saliva. Samples can also be derived from a population of individuals. The individuals can be humans, but can be any organism, plant or animal, eukaryotic or prokaryotic, viral or non-viral.
  
- [33] Any type of probe can be used for specific hybridization to the amplified polynucleotides which are bound to the beads. Fluorescently labeled probes are

useful because their analysis can be automated and can achieve high throughput. Fluorescence activated cell sorting (FACS) permits both the analysis and the isolation of different populations of beads. One type of fluorescently labeled probe that can be used is a modified molecular beacon probe. These probes have stem-loop structures and an attached fluorescent moiety on the probe, typically on one end of the probe, sometimes attached through a linker. Unlike standard molecular beacon probes, modified molecular beacon probes do not have a quenching moiety. The modified molecular beacon probe can have the fluorescent moiety attached on either end of the probe, 5' or 3'. One such probe will hybridize better to a wild-type sequence than to a mutant. Another such probe will hybridize better to a mutant sequence than to the wild type. Still other probes will preferably hybridize to one polymorphic variant over another.

[34] The method of the present invention provides a reliable and sensitive assay for measuring variations in genes and transcripts. It requires no instrumentation other than machines that are widely available. There are several other advantages of this approach. First, the sensitivity can be increased to meet the particular specifications of an assay simply by analyzing more beads. Such sensitivity is limited only by the error rate of the polymerases used for amplification. Second, the data obtained can be used not only to demonstrate that a variant is present in a particular population of DNA molecules, but also quantifies the fraction of variant DNA molecules in that population (Fig. 5A). Such quantification is not possible with techniques that destroy or ignore the wild type molecules as part of the assay, such as those that use allele specific priming or endonuclease digestion during PCR. Third, the beads containing variant alleles can easily be purified through flow sorting. Such recovery is difficult with digital techniques that count molecules deposited on microscope slides. And finally, the method is automatable.

[35] Several modifications of the basic principles described here can be envisioned that will further simplify the technology or widen its applications. For example, microemulsions were made by stirring water/oil/detergent mixes. The sizes of the

resultant aqueous compartments were somewhat heterogeneous, as illustrated in Fig. 2. A relatively large number of beads containing PCR products of both alleles are obtained from large compartments because they are more likely to contain >1 template molecule than smaller compartments. Though this is not a problem for the analysis of uncommon variants, it does pose a problem when the variant to be analyzed is present in a substantial fraction of the DNA molecules. For example, it is easy to distinguish a population containing 2% of allele A and 98% of allele B from one that contains 0% of allele A (Fig. 5A). But it is more difficult to distinguish a population that contains 48% of allele A and 52% of allele B from a population that contains 50% of allele A; the large number of heterozygote beads formed in the latter analysis diffuse the boundaries of the pure red and green channels. This limit to accuracy can be overcome through the preparation of more uniformly sized aqueous compartments. Sonication or pressure-driven emulsifiers can make more uniform compartments.

- [36] Though flow cytometry requires only seconds to minutes per sample, multiple parallel analyses could facilitate throughput. Novel particle counting designs may prove useful for this purpose. Another way to increase throughput would be to physically separate the beads that contained PCR products prior to flow cytometry. This could be accomplished with proteins such as antibodies or streptavidin that bind to modified nucleotides incorporated into the PCR product during amplification.
- [37] The methods of the invention can be applied to genes or transcripts of any organism or population of organisms. These include without limitation: humans, rodents, ungulates, mammals, primates, cows, goats, pigs, rats, mice, yeast, poultry, fish, shellfish, digs, cats, zebrafish, worms, algae. It can also be used to quantify epigenetic alterations, such as methylation, if DNA is first treated with bisulfite to convert methylated cytosine residues to thymidine. Beads generated from random fragments of whole genomes (24), rather than from individual genes as described above, could be used to identify gene segments that bind to specific DNA-binding proteins (25). And if the product beads are used in compartmentalized in vitro

transcription-translation reactions, variant proteins can be bound to beads containing the corresponding variant DNA sequences (23). This could allow facile flow cytometric evaluation of rare mutations using antibodies that distinguished between wild type and mutant gene products (26).

- [38] While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.

#### EXAMPLES

##### Example 1--Materials and Methods

- [39] Step 1 - Coupling oligonucleotides to beads. Superparamagnetic beads of  $1.05 \pm 0.1$   $\mu\text{m}$  in diameter, covalently bound to streptavidin, were purchased from Dynal Biotech, Inc. (650.01, Lake Success, NY). Beads were washed once with 1x PCR buffer (53286, Invitrogen, Carlsbad, CA) then suspended in Bind and Wash Buffer (BWB) (5 mM Tris-HCl, 0.5 mM EDTA, 1.0 M NaCl, pH 7.5). Beads were incubated in BWB for 30 min at room temperature in the presence of 10  $\mu\text{M}$  oligonucleotides (Supplementary Table 1). These oligonucleotides were modified with a dual biotin group at the 5' end with the biotin groups separated by a six-carbon linker (IDT, Coralville, IA). After binding, the beads were washed 3 times with 1x PCR buffer to thoroughly remove unbound oligonucleotides.
- [40] Step 2 - Preparing microemulsions. Microemulsions for PCR were prepared by slight modifications of previously described methods (14) (15). The oil phase was composed of 4.5% Span 80 (S6760, Sigma, St. Louis, MO), 0.40 % Tween 80 (Sigma S-8074), and 0.05% Triton X-100 (Sigma T-9284) in mineral oil (Sigma M-3516). The oil phase was freshly prepared each day. The aqueous phase consisted of 67 mM Tris-HCl (pH 8.8), 16.6 mM  $\text{NH}_4\text{SO}_4$ , 6.7 mM  $\text{MgCl}_2$ , 10 mM  $\beta$ -mercaptoethanol, 1



mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM dTTP, 0.05 uM forward primer, 25 uM reverse primer, 45 units Platinum Taq (Invitrogen 10966-034), various amounts of template DNA (see results), and ~108 oligonucleotide-coupled beads in a total volume of 300 ul. The forward primer was an oligonucleotide whose sequence was identical to the 3' 20 – 22 nt of that described in step 1 and was not modified with biotin.

- [41] Water-in-oil microemulsions were prepared by drop wise addition of 200 uL of the aqueous phase to 400 ul of the oil phase previously placed in a 2 ml round bottom cryogenic vial (430661, Corning, Corning, NY). The drop wise addition was performed over ~ one minute while the mixture was being stirred at 1400 RPM with a magnetic microstir bar (58948-353, VWR, Plainfield, NJ) on a VWR model 565 Magnetic Stirrer. After the addition of the aqueous phase, the mixture continued to be stirred for a total time of 30 minutes. Two emulsions were made at once by placing two tubes in a rack placed at the center of the magnetic stirrer.
- [42] Step 3 - PCR cycling. The emulsions were aliquotted into five wells of a 96 well PCR plate, each containing 100 ul. PCR was carried out under the following cycling conditions: 94°C for 2 minutes; 40 cycles of 94°C for 15 seconds, 57°C for 30 seconds, 70°C for 30 seconds. The PCR products analyzed in this study ranged from 189 to 239 bp.
- [43] Step 4 - Magnetic capture of beads. After PCR cycling, the microemulsion from five wells of a PCR plate were pooled and broken by the addition 800 ul of NX buffer (100 mM NaCl containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA) in a 1.5 ml tube (Corning 430909). After vortexing for ~20 sec. the beads were pelleted by centrifugation in a microcentrifuge at 8000 rpm (5000 g) for 90 seconds. The top oil phase and all but ~300 ul of the aqueous phase was removed from the tube and 600 ul of NX buffer was added. After vortexing for 20 sec. and centrifugation for 90 sec., the top oil phase and all but ~300 ul of the aqueous phase was removed. The addition of 600 ul NX buffer, vortexing, and centrifugation was repeated once more

and the top oil portion and all but ~300 ul of the aqueous phase was removed. The tube was then placed on a magnet (DynaL MPC-S) and the rest of the supernatant was carefully pipetted off. The beads were washed an additional 3 times with 1x PCR buffer using magnetic separation rather than centrifugation and finally resuspended in 100 ul of 1x PCR buffer.

- [44] Step 5 - Sequence differentiation. Two oligonucleotide probes were used for each reaction. One was 5'-labeled with 6-carboxyfluorescein (6-FAM) and was specific for one allele while the second was 5'-labeled with biotin and was specific for the other allele. Probes were synthesized by IDT. The 30 ul hybridization reactions contained 10 uM of each probe and 5 - 25 million beads in 1 x PCR buffer. Reactions were performed in PCR plates on a thermal cycler by heating to 94°C for 30 seconds then cooling to 75°C at a rate of 0.5°C per second, cooling to 45°C at 0.2°C per second, and finally cooled to 30°C at 1°C per second. All subsequent steps were performed at room temperature. The reactions were transferred to a 96 well Costar plate (Corning 3797) and placed on a 96 well magnet. Beads were collected magnetically by exposing them to the magnet for 2 minutes. The supernatant was removed and the beads washed 3 times with 1x PCR buffer by pipetting them and collecting for two minutes. They were finally resuspended in 100 ul B-PCR buffer (1mg/mL BSA in 1x PCR buffer). The beads were then incubated for 10 minutes in a total volume of 100 ul B-PCR buffer containing 3 ug of Alexa-488 rabbit anti-fluorescein antibody (Molecular Probes A-11090, Eugene, OR) and 3 ug of Nutraavidin labeled with phycoerythrin (Molecular Probes A-2660) in B-PCR buffer. The beads were washed three times and resuspended in B-PCR buffer as described above. They were then incubated for ten minutes in a total volume of 100 ul B-PCR buffer containing 6 ug of Alexa 488- conjugated chicken anti-rabbit antibody (Molecular Probes A-21441) and 3 ug of biotinylated goat anti-avidin antibody (BA-0300, Vector Laboratories, Burlingame, CA). The beads were washed three times and resuspended in B-PCR buffer as described above. They were then incubated for ten minutes in a total volume of 100 ul B-PCR buffer containing 3 ug of an Alexa 488-

conjugated goat anti-chicken antibody (Molecular Probes A-11039) and 3 ug of phycoerythrin-labeled streptavidin (Molecular Probes S-866). This solution was then washed an additional 3 times with 1x PCR buffer and resuspended in 20 ul of 1 X PCR buffer.

- [45] Step 6 - Flow Cytometry. The bead suspension was diluted to a concentration of ~ 106 -107 beads per ml in 10 mM Tris-HCl, 1 mM EDTA (351-010-131, Quality Biological, Inc., Gaithersburg, MD) and analyzed using a LSR instrument (BD Biosciences, Franklin Lakes, NJ). The instrument was set up for standard two-color analysis using an argon laser and optical filters that distinguished between the two fluorescent dyes. No spectral deconvolution was required as the major bead populations were well-separated. In some cases, scanning was performed with FACScan or FACSCalibur instruments (BD Biosciences), yielding equivalent results. Sorting was carried out with a FACS Vantage SE instrument (BD Biosciences).
- [46] Template preparation and sequence analyses. Human genomic DNA was purified with DNeasy (69504, Qiagen, Valencia, CA). RNA was purified with Quickprep (27-9255-01, Amersham Biosciences, Piscataway, NJ). Reverse transcription of RNA was performed using Superscript II reverse transcriptase (Invitrogen 18064014) according to the manufacturer's instructions. PCR using genomic DNA or reverse transcripts as templates was performed as described (7). PCR products to be used as templates for BEAMing or for sequencing were purified with QIAquick (Qiagen 28104). Sequencing reactions were performed using Big Dye v3.0 reagents (Applied Biosystems, Foster City, CA) and analyzed by capillary electrophoresis (Spectrumedix 9600, State College, PA).

#### Example 2--Results

- [47] Step 1 - Coupling oligonucleotides to beads. We used streptavidin-beads because of the simplicity of coupling biotinylated oligonucleotides to them. Oligonucleotides with just a single 5' biotin group were found to dissociate from the beads during temperature cycling, while oligonucleotides labeled with dual biotin groups at their 5'

end (separated by a six-carbon linker) were stable to cycling. As determined by fluoroscopic measurements of oligonucleotides doubly labeled with 6-FAM and biotin, ~105 oligonucleotide molecules were bound to each bead. We found that short oligonucleotides (20 bases) did not work as well for priming as longer ones (41 bp), perhaps because of steric hindrance at the bead surface. It is likely that amino-, sulfhydryl-, or carboxyl-modified oligonucleotides covalently coupled to beads modified with corresponding reactive groups could also function as bead-bound primers for BEAMing.

- [48] Step 2 - Preparing microemulsions. The size of the individual aqueous compartments ranged from less than 1 micron to >10 microns in diameter (Fig. 2). We estimated that an emulsion comprising 200 ul of aqueous solution and 400 ul of oil would contain  $\sim 3 \times 10^9$  compartments with an average diameter of 5 microns. Approximately 108 beads were included in each emulsion, so that only one in  $\sim 30$  compartments contained a bead. The optimal amount of template was experimentally determined to be  $\sim 5 \times 10^8$  molecules, so that one in  $\sim$ six compartments contained a template molecule.
- [49] Step 3 - PCR cycling. PCR priming by oligonucleotides coupled to beads was found to be very inefficient compared to the priming by the same oligonucleotides when free in solution. For this reason, a small amount of non-biotinylated forward primer identical in sequence to the biotinylated oligonucleotide coupled to the beads was included in the reactions. This facilitated the first few rounds of amplification of the single template within each aqueous compartment. In the absence of additional primer, no detectable amplification on the beads was generated. Conversely, if too much additional primer was included, no amplification on the beads occurred because of competition with the primers in solution. An excess of the reverse primer was included in the aqueous compartment to maximize the probability that bead-bound oligonucleotides extended by polymerase would serve as templates for further amplification cycles.

- [50] Step 4 - Magnetic capture of beads. There are several ways to break water-in-oil emulsions, including extraction with organics (14). We found that simply adding non-ionic detergents produced phase separations without any detectable modification of the beads or DNA molecules bound to them. By measuring the amount of DNA that could be released from the beads following restriction endonuclease digestion, we estimate that >10,000 extended PCR products were present, on average, per bead.
- [51] Step 5 - Sequence differentiation. Most fluorescence-based methods for distinguishing alleles in homogeneous or two-phase assays can be used to assess allelic variation captured on beads. These methods include single nucleotide extension, allele specific priming, or hybridization. We generally employed hybridization of fluorescein-conjugated or biotin-conjugated oligonucleotides for discrimination. As shown in Fig. 1 and Supplementary Table 1, these oligonucleotides had a stem-loop structure, with the middle of the loop containing the variant nucleotide(s). This design was based on studies of Molecular Beacons wherein a stem-loop structure was shown to markedly improve allelic discrimination (16). The oligonucleotides we used differed from Molecular Beacons in that there was no need for a quenching group. Such quenching is required for homogeneous assays when unhybridized oligonucleotides cannot be removed from the reactions prior to assay but is not necessary for solid phase assays such as those employed with beads.
- [52] Step 6 - Flow Cytometry. Optimum results in flow cytometry depend on high fluorescent signals on the beads. We generally enhanced the fluorescence emanating from the hybridization probes with secondary reagents. For example, Alexa 488—labeled antibodies were used to enhance the signals emanating from fluorescein-coupled oligonucleotide probes. Similarly, phycoerythrin-labeled streptavidin was used to generate a signal from biotin-labeled oligonucleotide probes. Flow cytometers equipped with two or three lasers and appropriate filters have the capacity to distinguish multi-allelic loci and to perform multiplex analysis of several genes simultaneously. The newest generation of flow cytometers can also analyze >70,000

events per second. In addition to the analytical power of flow cytometry, FACS instruments can separate specific populations of beads for further analysis.

Example 3-- Characteristics of microemulsions.

- [53] Pilot experiments demonstrated that simply stirring the water-oil mixtures described in Materials and Methods produced very stable microemulsions of a size compatible with that of the beads. In the experiment shown in Fig. 2, the aqueous compartment contained a blue dye and 1 micron magnetic beads that were labeled by binding to an oligonucleotide that was biotinylated at its 5' end and labeled with fluorescein at its 3' end. The appearance of emulsions immediately after their formation is shown in Fig. 2. As expected, this appearance was unchanged after temperature cycling during PCR (15). Most aqueous compartments contained no beads, as expected from the figures provided in the previous section. Those compartments that did contain beads generally contained only one, though a fraction contained more, as expected from a Poisson distribution and non-uniform aqueous compartment sizes. "Heterozygous" beads containing PCR products representing both alleles are produced when two or more DNA template molecules are contained within a single aqueous compartment. Such heterozygotes can compromise the accuracy of the analyses under some circumstances (see Discussion).

Example 4-- Detection of homozygotes and heterozygotes.

- [54] Fig. 3 shows typical results obtained with human DNA samples. The MID42 marker used in this experiment was chosen from a collection of diallelic short insertion/deletion polymorphisms assembled by Weber and colleagues (17). These alleles are particularly simple to distinguish with hybridization probes because the two alleles at each locus differ by ~ 4 bases. The probe for the longer (L) allele was labeled with fluorescein (green) and the probe for the shorter (S) allele labeled with phycoerythrin (red).

- [55] Fig. 3A shows a plot of the side scatter vs. forward scatter of beads following BEAMing. In general, >75% of beads were dispersed as single particles, with the remainder aggregated in groups of two or more. Subsequent flow cytometric analysis was confined to the singlet beads, gated as outlined in Fig. 3A.
- [56] Figs. 3B - D show density plots of gated beads generated with various templates. In Fig. 3B, a template from an individual homozygous for the L allele was included in the emulsion. Two populations of beads were apparent. 98 % of the beads contained no PCR product (black) and the remaining 2% fluoresced in the FL1 channel (colored green in Fig. 3). Fig. 3C represents the analysis of an individual homozygous for the S allele. Two populations of beads were again apparent, but this time the labeled population fluoresced in the FL2 channel (colored red in Fig. 3). Fig. 3D presents density plots from the analysis of an individual heterozygous at the MID42 locus. Four populations of beads are evident: the black region represents beads without any PCR product, the red region represents beads containing PCR products from the L allele, the green region represents beads containing PCR products from the S allele, and the blue region represents beads containing PCR products from both alleles. Beads containing PCR products from both alleles were derived from aqueous compartments which contained more than one template molecule. The number of blue beads increased in a non-linear fashion as more template molecules were added. At the extreme, when all aqueous compartments are saturated, virtually all beads will register as blue. Operationally, we found that the bead populations were most distinct when the number of beads containing any PCR product was < 10% of the total beads analyzed.

Example 5-- PCR products, genomic DNA or cDNA as templates.

- [57] The results shown in Fig. 3 were generated using PCR products made from human genomic DNA samples. As the ratio of the beads representing L alleles to those representing S alleles was 1.0 in this experiment, it was clear that the initial PCR did not preferentially amplify either allele. The use of PCR products rather than genomic

DNA permitted large numbers of alleles to be amplified from even small quantities of starting DNA. In general, 10 to 100 pg of PCR products of size 200 bp were found to be optimal for BEAMing, producing PCR-mediated extension of primers on ~1 to 10% labeled beads.

- [58] In some situations it might be useful to use genomic DNA rather than PCR products as templates for BEAMing. The data in Fig. 4A and B show flow cytometric data from an experiment wherein 10 ug or 1 ug of human genomic DNA was used as template for BEAMing at the MID42 locus. Patterns very similar to those shown in Fig. 3 were observed, though fewer beads were labeled than when PCR products were used as templates.
- [59] BEAMing could also be used to analyze variations in expression from the two alleles of a heterozygous individual. Heritable variations in the expression from individual alleles of the same gene have been shown to occur often in humans (18) and mice (19) and can have significant phenotypic effects (20). The results shown in Fig. 4C and D show that PCR products made from reverse-transcribed mRNA can be used for BEAMing. In this case, calpain-10 transcripts differing by a single nucleotide polymorphism (SNP) were analyzed. For SNPs like these, probes that incorporated an extra mismatched nucleotide adjacent to the polymorphic nucleotide (see Supplementary Table I) can enhance the distinction between alleles (21) (22). The results from two independent emulsions made with aliquots of the same RT-PCR product are shown to illustrate reproducibility. Though the number of beads that functioned as templates in BEAMing varied up to 3-fold among experiments with identical templates, the proportion of beads representing the two alleles was reproducible (775 A allele beads to 690 G allele beads in Fig. 4C and 1380 A allele beads to 1227 G allele beads in Fig. 4D) respectively).

Example 6-- Analysis of minor variants in a DNA population.

- [60] The analysis of uncommon variations is ideally suited for analysis via BEAMing because of the large number of molecules that can be independently analyzed while



retaining a high signal-to-noise ratio. Fig. 5A shows representative data from templates representing 1%, 2%, 3%, and 4% of the L allele of MID42. The linearity of these measurements, with a correlation coefficient of 0.99, demonstrates the utility of this approach for such applications. We also applied this analysis to the detection of KRAS and could easily observe 0.1% mutants when spiked into a population of wt molecules (data not shown).

- [61] The rare beads representing the mutant alleles could not only be quantified but could also be purified for subsequent analysis. As a demonstration, samples of the beads enumerated in Fig. 5A were additionally assessed using a flow cytometer equipped with sorting capabilities. Beads were sorted and individual beads used as templates for conventional PCR using the same primers employed for BEAMing. As each bead contains thousands of bound template molecules, single beads were expected to generate robust PCR products (23) and this was experimentally confirmed. These PCR products were then subjected to sequencing. As shown in Fig. 5B and C, green and red beads generated PCR products exclusively of the L and S types, respectively.

#### References cited:

1. Collins, F. S., Patrinos, A., Jordan, E., Chakravarti, A., Gesteland, R. & Walters, L. (1998) *Science* **282**, 682-689.
2. Vogelstein, B. & Kinzler, K. W. (2002) *The Genetic Basis of Human Cancer* (McGraw-Hill, Toronto).
3. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P. & et al. (1991) *Science* **252**, 706-709.
4. Ahlquist, D. A. & Shuber, A. P. (2002) *Clin Chim Acta* **315**, 157-168.

5. Sidransky, D. (2002) *Nat Rev Cancer* **2**, 210-219.
6. Chomyn, A. & Attardi, G. (2003) *Biochem Biophys Res Commun* **304**, 519-529.
7. Vogelstein, B. & Kinzler, K. W. (1999) *Proc Natl Acad Sci U S A* **96**, 9236-9241.
8. Mitra, R. D., Butty, V. L., Shendure, J., Williams, B. R., Housman, D. E. & Church, G. M. (2003) *Proc Natl Acad Sci U S A* **100**, 5926-5931.
9. Li, H. H., Gyllenstein, U. B., Cui, X. F., Saiki, R. K., Erlich, H. A. & Arnheim, N. (1988) *Nature* **335**, 414-417.
10. Ruano, G., Kidd, K. K. & Stephens, J. C. (1990) *Proc Natl Acad Sci U S A* **87**, 6296-6300.
11. Jeffreys, A. J., Allen, M. J., Armour, J. A., Collick, A., Dubrova, Y., Fretwell, N., Guram, T., Jobling, M., May, C. A., Neil, D. L. & et al. (1995) *Electrophoresis* **16**, 1577-1585.
12. Lizardi, P. M., Huang, X., Zhu, Z., Bray-Ward, P., Thomas, D. C. & Ward, D. C. (1998) *Nat Genet* **19**, 225-232.
13. Jurinke, C., van den Boom, D., Cantor, C. R. & Koster, H. (2002) *Adv Biochem Eng Biotechnol* **77**, 57-74.
14. Tawfik, D. S. & Griffiths, A. D. (1998) *Nat Biotechnol* **16**, 652-656.
15. Ghadessy, F. J., Ong, J. L. & Holliger, P. (2001) *Proc Natl Acad Sci U S A* **98**, 4552-4557.
16. Tyagi, S., Bratu, D. P. & Kramer, F. R. (1998) *Nat Biotechnol* **16**, 49-53.
17. Weber, J. L., David, D., Heil, J., Fan, Y., Zhao, C. & Marth, G. (2002) *Am J Hum Genet* **71**, 854-862.
18. Yan, H., Yuan, W., Velculescu, V. E., Vogelstein, B. & Kinzler, K. W. (2002) *Science* **297**, 1143.
19. Cowles, C. R., Joel, N. H., Altshuler, D. & Lander, E. S. (2002) *Nat Genet* **32**, 432-437.
20. Yan, H., Dobbie, Z., Gruber, S. B., Markowitz, S., Romans, K., Giardiello, F. M., Kinzler, K. W. & Vogelstein, B. (2002) *Nat Genet* **30**, 25-26.
21. Okimoto, R. & Dodgson, J. B. (1996) *Biotechniques* **21**, 20-26.
22. Luo, J., Bergstrom, D. E. & Barany, F. (1996) *Nucleic Acids Res* **24**, 3071-3078.

23. Sepp, A., Tawfik, D. S. & Griffiths, A. D. (2002) *FEBS Lett* **532**, 455-458.
24. Kinzler, K. W. & Vogelstein, B. (1989) *Nucleic Acids Res* **17**, 3645-3653.
25. Yang, X., Li, X., Prow, T. W., Reece, L. M., Bassett, S. E., Luxon, B. A., Herzog, N. K., Aronson, J., Shope, R. E., Leary, J. F. & Gorenstein, D. G. (2003) *Nucleic Acids Res* **31**, e54.
26. Gite, S., Lim, M., Carlson, R., Olejnik, J., Zehnbaauer, B. & Rothschild, K. (2003) *Nat Biotechnol* **21**, 194-197.

We Claim:

1. A composition comprising a plurality of beads, wherein each of said plurality of beads comprises a plurality of bound polynucleotides, wherein the polynucleotides in the composition are heterogeneous, and wherein on at least 1 % of said beads the plurality of bound polynucleotides is homogeneous.
2. The composition of claim 1 wherein on at least 5 % of said beads the plurality of bound polynucleotides is homogeneous.
3. The composition of claim 1 wherein on at least 10 % of said beads the plurality of bound polynucleotides is homogeneous.
4. The composition of claim 1 wherein on at least 50 % of said beads the plurality of bound polynucleotides is homogeneous.
5. The composition of claim 1 wherein the plurality of bound polynucleotides is greater than 100.
6. The composition of claim 1 which is a liquid.
7. The composition of claim 6 which comprises agarose.
8. The composition of claim 1 wherein the polynucleotides in the composition differ by a single nucleotide polymorphism (SNP).
9. The composition of claim 1 wherein the polynucleotides in the composition differ in the presence or absence of a mutation.
10. The composition of claim 1 wherein the polynucleotides in the composition differ in the presence or absence of an insertion.
11. The composition of claim 1 wherein the polynucleotides in the composition differ by the presence or absence of a polymorphism.
12. The composition of claim 1 wherein the beads are magnetic.
13. The composition of claim 1 wherein at least one species of polynucleotide is labeled with a fluorescent dye.
14. The composition of claim 13 wherein the labeling is via a labeled oligonucleotide.

15. The composition of claim 13 wherein the labeling is via one or more labeled antibodies.
16. The composition of claim 1 wherein the bound polynucleotides were made by amplification of a template in a test sample, wherein the beads on which the plurality of bound polynucleotides is homogeneous comprise at least a first and a second species of polynucleotide, wherein the beads comprising the first species of polynucleotide and the beads comprising the second species of polynucleotide are present in the composition in the same ratio as the first and second species of polynucleotide were present in the test sample.
17. A liquid composition comprising a plurality of microemulsions forming aqueous compartments wherein at least a portion of said aqueous compartments comprise:  
a bead;  
a polynucleotide template; and  
oligonucleotide primers for amplifying said template;  
wherein at least a portion of the oligonucleotide primers is bound to the bead.
18. The liquid composition of claim 17 which comprises forward and reverse oligonucleotide primers.
19. The liquid composition of claim 17 wherein said aqueous compartments have an average diameter of 0.5 to 50 microns.
20. The liquid composition of claim 17 wherein at least one in 10,000 of said aqueous compartments comprise a bead.
21. The liquid composition of claim 17 wherein from 1/100 to 1 of said aqueous compartments comprise a bead.
22. The liquid composition of claim 17 wherein from 1/50 to 1 of said aqueous compartments comprise a polynucleotide template molecule.
23. The liquid composition of claim 17 wherein the bead is magnetic.
24. The liquid composition of claim 17 wherein the average number of template molecules per aqueous compartment is less than 1.
25. The liquid composition of claim 17 further comprising a DNA polymerase and deoxyribonucleotides.

26. The liquid composition of claim 17 wherein the average diameter of said aqueous compartments is from 1 to 10 microns, inclusive.
27. The liquid composition of claim 17 wherein the average diameter of said aqueous compartments is from 11 to 100 microns, inclusive.
28. The liquid composition of claim 17 wherein the average diameter of said aqueous compartments is about 5 microns.
29. The liquid composition of claim 17 wherein each oligonucleotide primer is at least 12 nucleotides in length.
30. The liquid composition of claim 17 wherein each oligonucleotide primer is from 25 to 55 nucleotides.
31. The liquid composition of claim 17 wherein binding of said oligonucleotide primers to said bead is covalent.
32. The liquid composition of claim 17 wherein binding of said oligonucleotide primers to said bead is via a biotin-streptavidin binding pair.
33. The liquid composition of claim 32 wherein said forward or reverse oligonucleotide primers that are bound to said bead comprise at least two biotin moieties.
34. The liquid composition of claim 17 wherein the aqueous compartments comprise agarose.
35. A method for analyzing nucleotide sequence variations, comprising:
  - forming microemulsions comprising one or more species of analyte DNA molecules;
  - amplifying analyte DNA molecules in the microemulsions in the presence of reagent beads, wherein the reagent beads are bound to a plurality of molecules of a primer for amplifying the analyte DNA molecules, whereby product beads are formed which are bound to a plurality of copies of one species of analyte DNA molecule;
  - separating the product beads from analyte DNA molecules which are not bound to product beads;
  - determining a sequence feature of the one species of analyte DNA molecule which is bound to the product beads.

36. The method of claim 35 further comprising the step of isolating product beads which are bound to a plurality of copies of a first species of analyte DNA molecule from product beads which are bound to a plurality of copies of a second species of analyte DNA molecule.
37. The method of claim 36 wherein the step of isolating is performed using fluorescence activated cell sorting.
38. The method of claim 36 further comprising the step of recovering the first species of analyte DNA molecule from the product beads.
39. The method of claim 36 further comprising the step of amplifying the first species of analyte DNA molecule from the isolated product beads.
40. The method of claim 38 further comprising the step of determining the sequence of the first species of analyte DNA molecule.
41. The method of claim 35 wherein the step of amplifying converts less than 10 % of the reagent beads present in the microemulsions into product beads.
42. The method of claim 35 wherein prior to the step of separating, the microemulsions are broken by addition of one or more detergents.
43. The method of claim 35 wherein the step of determining is performed by hybridization to oligonucleotide probes which are differentially labeled.
44. The method of claim 35 wherein the relative or absolute amounts of product beads comprising one or more sequence features is determined.
45. The method of claim 44 wherein the relative or absolute amounts are determined using flow cytometry.
46. The method of claim 35 wherein the step of amplifying employs additional copies of the primer which are not bound to the reagent bead.
47. The method of claim 35 wherein the analyte DNA molecules are genomic DNA.
48. The method of claim 35 wherein the analyte DNA molecules are cDNA.
49. The method of claim 35 wherein the analyte DNA molecules are PCR products made from genomic DNA.
50. The method of claim 35 wherein the analyte DNA molecules are PCR products made from cDNA.

51. The method of claim 35 wherein the analyte DNA molecules are derived from a single individual.
52. The method of claim 35 wherein the analyte DNA molecules are derived from a population of individuals.
53. The method of claim 35 wherein the reagent beads are magnetic.
54. The method of claim 35 wherein the step of determining a sequence feature is performed by extension of a primer with one or more labeled deoxyribonucleotides.
55. A probe for use in hybridization to a polynucleotide that is bound to a solid support, comprising:  
an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends, wherein said oligonucleotide does not comprise a quenching agent at the opposite 5' or 3' end.
56. The probe of claim 55 which hybridizes to a wild-type selected genetic sequence better than to a mutant selected genetic sequence.
57. The probe of claim 55 which hybridizes to a mutant genetic sequence better than to a wild-type genetic sequence.
58. A pair of molecular probes comprising:  
a first oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends, wherein said first oligonucleotide does not comprise a quenching agent at the opposite 5' or 3' end, wherein said first oligonucleotide hybridizes to a wild-type selected genetic sequence better than to a mutant selected genetic sequence; and  
a second oligonucleotide with a stem-loop structure having a second photoluminescent dye at one of the 5' or 3' ends, wherein said second oligonucleotide does not comprise a quenching agent at the opposite 5' or 3' end, wherein said second oligonucleotide hybridizes to the mutant selected genetic sequence better than to the wild-type selected genetic sequence;  
wherein the first and the second photoluminescent dyes are distinct.
59. A method for isolating nucleotide sequence variants, comprising:



forming microemulsions comprising one or more species of analyte DNA molecules;

amplifying analyte DNA molecules in the microemulsions in the presence of reagent beads, wherein the reagent beads are bound to a plurality of molecules of a primer for amplifying the analyte DNA molecules, whereby product beads are formed which are bound to a plurality of copies of one species of analyte DNA molecule;

separating the product beads from analyte DNA molecules which are not bound to product beads;

isolating product beads which are bound to a plurality of copies of a first species of analyte DNA molecule from product beads which are bound to a plurality of copies of a second species of analyte DNA molecule.


60. The method of claim 59 wherein the step of isolating is performed using fluorescence activated cell sorting.
61. The method of claim 59 further comprising the step of recovering the first species of analyte DNA molecule from the product beads.
62. The method of claim 59 further comprising the step of amplifying the first species of analyte DNA molecule from the isolated product beads.
63. The method of claim 59 further comprising the step of determining the sequence of the first species of analyte DNA molecule.

**METHOD AND COMPOSITIONS FOR DETECTION AND ENUMERATION OF  
GENETIC VARIATIONS**

**Abstract of the Invention**

Many areas of biomedical research depend on the analysis of uncommon variations in individual genes or transcripts. Here we describe a method that can quantify such variation at a scale and ease heretofore unattainable. Each DNA molecule in a collection of such molecules is converted into a single particle to which thousands of copies of DNA identical in sequence to the original are bound. This population of beads then corresponds to a one-to-one representation of the starting DNA molecules. Variation within the original population of DNA molecules can then be simply assessed by counting fluorescently-labeled particles via flow cytometry. Millions of individual DNA molecules can be assessed in this fashion with standard laboratory equipment. Moreover, specific variants can be isolated by flow sorting and employed for further experimentation. This approach can be used for the identification and quantification of rare mutations as well as to study variations in gene sequences or transcripts in specific populations or tissues.

## Figure Legends



**FIG. 1 Schematic of BEAMing.** Step 1- Magnetic beads covalently coated with streptavidin are bound to biotinylated oligonucleotides ("oligos"). Step 2 - An aqueous mix containing all the necessary components for PCR plus primer-bound beads and template DNA are stirred together with an oil/detergent mix to create microemulsions. The aqueous compartments (white circles in the gray oil layer) contain an average of <1 template molecule and <1 bead. Red and green templates represent two template molecules whose sequences differ by one or many nucleotides. Step 3 - The microemulsions are temperature cycled as in a conventional PCR. If a DNA template and a bead are present together in a single aqueous compartment, the bead bound oligonucleotides act as primers for amplification. The straight red and green lines connected to the beads represent extension products from the two different kinds of templates. Step 4 - The emulsions are broken and the beads are purified with a magnet. Step 5 - After denaturation, the beads are incubated with oligonucleotides that can distinguish between the sequences of the different kinds of templates. Fluorescently-labeled antibodies are then used to label the bound hybridization probes. This renders the beads containing PCR product as red or green upon appropriate laser excitation. Step 6 - Flow cytometry is used to count the red and green beads.







FIG. 2 Photograph of a typical microemulsion. Microemulsions were made as described in Materials and Methods with the exception that the aqueous compartments contained cascade blue-labeled dCTP and the beads were pre-labeled with phycoerythrin (red) or Alexa 488 (green). One  $\mu$ l of microemulsion was deposited in 1  $\mu$ l of oil on a microscope slide prior to photography. Of the seven aqueous compartments visible in this picture, two contain beads. Note the heterogeneous size of the aqueous compartments (beads are 1.05 microns in diameter).



**FIG. 3** Density plots of flow cytometric data obtained from BEAMing. The locus queried in this experiment was MID42 and PCR products generated from genomic DNA were used as templates in the microemulsions. (A) Forward scatter (FSC) and side scatter (SSC) of all beads show that ~80% of the total beads are singlets, with most of the remaining beads aggregated as doublets. The "noise" is instrumental and is observed with blank samples containing no beads. The instrument output was gated so that only singlets were analyzed for fluorescence analysis. The patterns observed from an individual homozygous for the L allele (A), homozygous for the S allele (B), and heterozygous for L and S (D) are shown in (B), (C), and (D), respectively. The regions containing beads hybridizing to the L and S allele probes are labeled green and red, respectively. The region containing beads that did not hybridize to any probe is black and the region containing beads that hybridized to both probes is blue. The blue beads arose from aqueous compartments in which both types of template molecules were present. The proportion of singlet beads that hybridized to at least one of the probes was 2.9%, 4.3%, and 20.3% in (B) to (D), respectively. The FSC and SSC plots in (A) represent the same beads analyzed in (D).



**FIG. 4** Density plots of BEAMing using genomic DNA or RT-PCR products as templates. The data in (A) and (B) were generated by including 10 and 1 ug of human genomic DNA, respectively, in the microemulsions, querying the *MID42* locus. The data in (C) and (D) were generated using emulsions that contained ~ 50 pg of PCR products synthesized from cDNA of lymphoblastoid cells, querying the *calpain-10* locus. The green and red regions correspond to the L and S alleles for *MID42* and to the A and G alleles for *calpain-10*. The number of beads in the outlined regions containing red or green beads is shown in each case. The proportion of singlet beads that hybridized to at least one of the probes was 1.2%, 0.6%, 6.8% and 4.2% in (A) to (D), respectively. The outlined regions used for counting in (A) and (B) were identical, as were those used for (C) and (D). Beads that did not hybridize to any probe were gated out and therefore not evident in the graphs, while the region containing beads that hybridized to both probes is labeled blue.



**Fig. 5** Detection and validation of variants present in a minor fraction of the DNA population. (A) Mixtures of PCR products containing 0% to 4% L alleles of MID42 were used for BEAMing. Flow cytometry such as that shown in Fig. 3 was used to determine the fraction of singlet beads that were red (y-axis). The proportion of singlet beads that hybridized to at least one of the probes varied from 3.2% to 4.3%. (B) Beads were sorted with the FACS Vantage SE instrument and individual red or green beads were used as templates for conventional PCR employing the forward and reverse primers listed in Supplementary Table I. Red beads generated only the S allele sequence while green beads generated only the L allele sequence.

Fig. 6A





Fig 6B





**Table I Oligonucleotides**

<b>Locus</b>	<b>Oligonucleotide*</b>	<b>Modification</b>	<b>Use**</b>
<i>MID42</i>	5'-tactatgtattatacgttaagacctctatgaatgaatgta	5' Dual biotin	Bound to Beads
<i>MID42</i>	5'-cgttaagacctctatgaatgaatgta	none	Forward Primer for PCR
<i>MID42</i>	5'-gaaaggtaagtacagggaaagg	none	Reverse Primer for PCR
<i>MID42</i>	5'-cacgcagattgaattaacAGTTagtacaaagacacgtg	5' 6-FAM	Hybridization probe for L allele
<i>MID42</i>	5'-cacgcagattgaattaacaggtacaagacacgtg	5' Biotin	Hybridization probe for S allele
<i>Calpain-10</i>	5'-agggtcccagagggtggaaggagccaggagccacccccactgctgctg	5' Dual Biotin	Bound to Beads
<i>Calpain-10</i>	5'-agggtcccagagggtggaag	none	Forward Primer for PCR
<i>Calpain-10</i>	5'-ttcgtatggctcactgtgaag	none	Reverse Primer for PCR
<i>Calpain-10</i>	5'-cacggtagggtgctTgcaggcagcgtg	5' 6-FAM	Hybridization probe for A allele
<i>Calpain-10</i>	5'-cacggtagggtgccCgcaggcagcgtg	5' Biotin	Hybridization probe for G allele
<i>KRAS2</i>	5'-ttcgtccacaaaaatgattctgaattagctgtatcgtcaagg	5' Dual Biotin	Bound to Beads
<i>KRAS2</i>	5'-agaatggctcctgcaccagtaa	none	Reverse Primer for PCR
<i>KRAS2</i>	5'-catgttctaataatagtcacatttca	none	Forward Primer for PCR
<i>KRAS2</i>	5'-cacgggagctGGTGGCgtagcgtg	5' 6-FAM	Hybridization probe for wt allele
<i>KRAS2</i>	5'-ccacgggagctgatggcgtagcgtg	5' Biotin	Hybridization probe for mutant allele

\*Bases in upper case represent allelic differences.

\*\*Hybridization probes each contained 4 bases at their 5' and 3' ends to form hairpins, as explained in the text.

July 08, 2004

PCT DIVISION  
34 CHEIMIN DES COLUMBETTES  
GENEVA, 1211  
GENEVA, 20, SWITZERLAND

This is to inform you that the document requested in your order dated 07-06-2004 is a true reproduction of the official office record copy of that document:

60467210 CERTIFIED PCT APP AS FILED-MAIL 1

- ☐ The enclosed office document is a reproduction from the official office record copy and has been recorded using high quality scanning or microfilm equipment. Copies of page/papers that were not scannable have not been included, nor have pages/papers received after the original filing date. Copies of these pages/papers may be ordered separately.
- ☒ The enclosed document is a reproduction of the best available source of the official office record copy of that document.

If you have any questions or need additional information, please contact our Customer Service Department.

*Mailing Address:*

Mail Stop Document Services,  
Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

*Delivery Address:*

U.S. Patent and Trademark Office  
Office of Public Records, Customer Service  
1213 Jefferson Davis Highway, Suite 300  
Arlington VA 22202

Order your copies of USPTO documents on the Web. It's fast, easy, and secure! Go to  
(<http://ebiz1.uspto.gov/oems25p/index.html>) and order today!

Voice: (703) 308-9726      Fax: (703) 308-7048      E-Mail: <mailto:DSD@USPTO.GOV>  
Ref:MS 1191821